SEC Form 4 · accession 0001144204-15-011077
Aevi Genomic Medicine, Inc. · GNMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F Cola
Officer — President and CEO · Director
Period of report
Feb 18, 2015
Accepted (ET)
Feb 20, 2015 · 6:09 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001138776
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option Award (right to buy)F1 | $7.01 | Feb 18, 2015 | A | 292,087 | A | — | Feb 18, 2025 | Common Stock | 292,087 | 292,087 | D |
Explanation of responses
- F1Of these options, 42,087 were issued to the reporting person (at his election) in lieu of an annual cash bonus for 2014 of $157,500 and vested on the grant date, and the remaining 250,000 options vest in four equal installments on February 18, 2016, 2017, 2018 and 2019.
Remarks
Exhibit 24 - Power of Attorney